Binding mode analysis and enrichment studies on homology models of the human histamine H4 receptor.

Ligand-supported homology models of the human histamine H4 receptor (hH4R) were developed based on the crystal structure of bovine rhodopsin and different known H4 ligands (histamine, OUP-16, JNJ7777120). Enrichment tests were performed to analyze whether our hH4R models can select known actives from random decoys. The impact of receptor conformation and the effect of different sets of random decoys, docking methods (FlexX, FlexX-Pharm) and scoring functions (FlexX-Score, D-Score, PMF-Score, G-Score, ChemScore) were investigated. We found that two agonists (histamine and OUP-16) form complementary interactions with Asp94 (3.32), Glu182 (5.46) and Thr323 (6.55), whereas JNJ7777120 interacts with Asp94 (3.32) and Glu182 (5.46) only. These results suggest a role of Thr323 (6.55) in ligand binding and presumably also in receptor activation. The models optimized in the presence of an agonist (histamine) and an antagonist (JNJ7777120) were compared in more detail. We conclude that the ligand used in the model building process can significantly influence the efficacy of virtual screening.

[1]  F. Gantner,et al.  Histamine H4 and H2 Receptors Control Histamine-Induced Interleukin-16 Release from Human CD8+ T Cells , 2002, Journal of Pharmacology and Experimental Therapeutics.

[2]  M Rarey,et al.  Detailed analysis of scoring functions for virtual screening. , 2001, Journal of medicinal chemistry.

[3]  I. D. de Esch,et al.  Synthesis and structure-activity relationships of indole and benzimidazole piperazines as histamine H(4) receptor antagonists. , 2004, Bioorganic & medicinal chemistry letters.

[4]  L B Hough,et al.  Genomics meets histamine receptors: new subtypes, new receptors. , 2001, Molecular pharmacology.

[5]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[6]  T. Klabunde,et al.  Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. , 2005, Journal of medicinal chemistry.

[7]  C. Sander,et al.  Quality control of protein models : directional atomic contact analysis , 1993 .

[8]  Andreas Evers,et al.  Virtual screening of biogenic amine-binding G-protein coupled receptors: comparative evaluation of protein- and ligand-based virtual screening protocols. , 2005, Journal of medicinal chemistry.

[9]  R. Horuk,et al.  Structure Function Differences in Nonpeptide CCR1 Antagonists for Human and Mouse CCR1 , 2003, The Journal of Immunology.

[10]  F. Monsma,et al.  Molecular modeling and site-specific mutagenesis of the histamine-binding site of the histamine H4 receptor. , 2002, Molecular pharmacology.

[11]  Xiang-Qun Xie,et al.  3D structural model of the G‐protein‐coupled cannabinoid CB2 receptor , 2003, Proteins.

[12]  B. Shoichet,et al.  Information decay in molecular docking screens against holo, apo, and modeled conformations of enzymes. , 2003, Journal of medicinal chemistry.

[13]  Nicholas J. Carruthers,et al.  Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. , 2001, Molecular pharmacology.

[14]  James J. Chambers,et al.  A homology-based model of the human 5-HT2A receptor derived from an in silico activated G-protein coupled receptor , 2002, J. Comput. Aided Mol. Des..

[15]  Kirstin Jöhren,et al.  A model of the human M2 muscarinic acetylcholine receptor , 2002, J. Comput. Aided Mol. Des..

[16]  Dawoon Jung,et al.  Virtual docking approaches to protein kinase B inhibition. , 2005, Journal of medicinal chemistry.

[17]  Prashant V Desai,et al.  Homology modeling of G-protein-coupled receptors and implications in drug design. , 2006, Current medicinal chemistry.

[18]  Antti Poso,et al.  Development of a 3D model for the human cannabinoid CB1 receptor. , 2004, Journal of medicinal chemistry.

[19]  H Hayashi,et al.  Site-directed mutagenesis of the histamine H1 receptor: roles of aspartic acid107, asparagine198 and threonine194. , 1994, Biochemical and biophysical research communications.

[20]  Yi-Jun Guo,et al.  Molecular basis for the interaction of histamine with the histamine H2 receptor. , 1992, The Journal of biological chemistry.

[21]  Tímea Polgár,et al.  Virtual screening for beta-secretase (BACE1) inhibitors reveals the importance of protonation states at Asp32 and Asp228. , 2005, Journal of medicinal chemistry.

[22]  Xueliang Fang,et al.  Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach. , 2003, Journal of medicinal chemistry.

[23]  V. Setola,et al.  Discovery of a novel member of the histamine receptor family. , 2001, Molecular pharmacology.

[24]  G. Klebe,et al.  Ligand-supported homology modelling of protein binding-sites using knowledge-based potentials. , 2003, Journal of molecular biology.

[25]  J Hoflack,et al.  The Binding Site of Neuropeptide Vasopressin V1a Receptor , 1995, The Journal of Biological Chemistry.

[26]  C. M. Davenport,et al.  Cloning, expression, and pharmacological characterization of a novel human histamine receptor. , 2001, Molecular pharmacology.

[27]  K. Lundstrom.  Structural genomics of GPCRs. , 2005, Trends in biotechnology.

[28]  Terry P Lybrand,et al.  Three-dimensional models for beta-adrenergic receptor complexes with agonists and antagonists. , 2003, Journal of medicinal chemistry.

[29]  Y. Masuho,et al.  Molecular Cloning and Characterization of a Novel Type of Histamine Receptor Preferentially Expressed in Leukocytes* , 2000, The Journal of Biological Chemistry.

[30]  A. Yamatodani,et al.  Efficient synthesis of trans- or cis-4(5)-(5-aminomethyltetrahydrofuran-2-yl)imidazoles via diazafulvene intermediates: synthetic approach toward human histamine H4)-ligands. , 2003, Chemical & pharmaceutical bulletin.

[31]  Jean-François Guichou,et al.  Structure-based design, synthesis, and biological evaluation of novel inhibitors of human cyclophilin A. , 2006, Journal of medicinal chemistry.

[32]  H. Kotani,et al.  Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype. , 2002, The Journal of clinical investigation.

[33]  R. Thurmond,et al.  Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation , 2004, British journal of pharmacology.

[34]  N. Campillo,et al.  Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study. , 2005, European journal of medicinal chemistry.

[35]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[36]  P Panula,et al.  Expression of histidine decarboxylase and cellular histamine-like immunoreactivity in rat embryogenesis. , 1995, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[37]  D. E. Clark,et al.  A virtual screening approach to finding novel and potent antagonists at the melanin-concentrating hormone 1 receptor. , 2004, Journal of medicinal chemistry.

[38]  G. Klebe,et al.  Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. , 2004, Journal of medicinal chemistry.

[39]  T. Williams,et al.  Histamine induces cytoskeletal changes in human eosinophils via the H4 receptor , 2003, British journal of pharmacology.

[40]  B. Noszál,et al.  Nitrogen-protonation microequilibria and C(2)-deprotonation microkinetics of histidine, histamine, and related compounds , 1991 .

[41]  C. Ganellin.  The tautomer ratio of histamine , 1973, The Journal of pharmacy and pharmacology.

[42]  J. A. Jablonowski,et al.  The first potent and selective non-imidazole human histamine H4 receptor antagonists. , 2003, Journal of medicinal chemistry.

[43]  K. Jacobson,et al.  Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling. , 2004, Journal of medicinal chemistry.

[44]  Gerhard Klebe,et al.  Ligand-supported homology modeling of g-protein-coupled receptor sites: models sufficient for successful virtual screening. , 2004, Angewandte Chemie.

[45]  Kurt Kristiansen,et al.  Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. , 2004, Pharmacology & therapeutics.

[46]  Alessandro Pedretti,et al.  Binding site analysis of full-length alpha1a adrenergic receptor using homology modeling and molecular docking. , 2004, Biochemical and biophysical research communications.

[47]  Prasad V. Bharatam,et al.  New leads for selective GSK-3 inhibition: pharmacophore mapping and virtual screening studies , 2006, J. Comput. Aided Mol. Des..

[48]  Marion Gurrath,et al.  Molecular modelling studies on the ORL1-receptor and ORL1-agonists , 2003, J. Comput. Aided Mol. Des..

[49]  R. Leurs,et al.  Lysine200 located in the fifth transmembrane domain of the histamine H1 receptor interacts with histamine but not with all H1 agonists. , 1995, Biochemical and biophysical research communications.

[50]  Thomas Lengauer,et al.  A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.

[51]  P. Desai,et al.  Histamine H4 Receptor Mediates Chemotaxis and Calcium Mobilization of Mast Cells , 2003, Journal of Pharmacology and Experimental Therapeutics.

[52]  A. Watts,et al.  The ring of the rhodopsin chromophore in a hydrophobic activation switch within the binding pocket. , 2004, Journal of molecular biology.

[53]  Jeremy L Jenkins,et al.  Virtual screening to enrich hit lists from high‐throughput screening: A case study on small‐molecule inhibitors of angiogenin , 2002, Proteins.

[54]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[55]  J. Wendoloski,et al.  Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening. , 2004, Journal of medicinal chemistry.

[56]  J. Schwartz,et al.  Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor , 1983, Nature.

[57]  R. Leurs,et al.  Therapeutic potential of histamine H3 receptor agonists and antagonists. , 1998, Trends in pharmacological sciences.

[58]  Kenneth A Jacobson,et al.  Docking studies of agonists and antagonists suggest an activation pathway of the A3 adenosine receptor. , 2006, Journal of molecular graphics & modelling.

[59]  F. Sanz,et al.  Novel approaches for modeling of the A1 adenosine receptor and its agonist binding site , 2004, Proteins.

[60]  M. Babina,et al.  Human skin mast cells express H2 and H4, but not H3 receptors. , 2004, The Journal of investigative dermatology.

[61]  R. Thurmond,et al.  The histamine H4 receptor as a new therapeutic target for inflammation. , 2005, Trends in pharmacological sciences.

[62]  D. Voehringer,et al.  Type 2 immunity reflects orchestrated recruitment of cells committed to IL-4 production. , 2004, Immunity.

[63]  Michael R. Braden,et al.  Molecular Interaction of Serotonin 5-HT2A Receptor Residues Phe339(6.51) and Phe340(6.52) with Superpotent N-Benzyl Phenethylamine Agonists , 2006, Molecular Pharmacology.

[64]  F. Monsma,et al.  Cloning and characterization of a novel human histamine receptor. , 2001, The Journal of pharmacology and experimental therapeutics.

[65]  I. Tuñón,et al.  Structural and vibrational study of the tautomerism of histamine free-base in solution. , 2003, Journal of the American Chemical Society.

[66]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.